NEW YORK ( TheStreet) -- Oncothyreon (Nasdaq: ONTY) hit a new 52-week low Monday as it is currently trading at $3.98, below its previous 52-week low of $4 with 266,121 shares traded as of 12:08 p.m. ET. Average volume has been 1.4 million shares over the past 30 days. Oncothyreon has a market cap of $237.1 million and is part of the health care sector and drugs industry. Shares are down 45.8% year to date as of the close of trading on Friday. Oncothyreon Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic products for the treatment of cancer. Its primary product candidate, Stimuvax is in Phase III clinical trials for the treatment of non-small cell lung cancer.